UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000021325
Receipt number R000024138
Scientific Title Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal metastasis from colorectal or appendiceal cancer: a feasibility study
Date of disclosure of the study information 2016/03/03
Last modified on 2019/08/13 19:46:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy
for peritoneal metastasis from colorectal or appendiceal cancer: a feasibility study

Acronym

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy
for peritoneal metastasis from colorectal or appendiceal cancer: a feasibility study

Scientific Title

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy
for peritoneal metastasis from colorectal or appendiceal cancer: a feasibility study

Scientific Title:Acronym

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy
for peritoneal metastasis from colorectal or appendiceal cancer: a feasibility study

Region

Japan


Condition

Condition

Peritoneal metastasis from colorectal or appendiceal cancer

Classification by specialty

Hematology and clinical oncology Surgery in general Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the feasibility and safety of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy
for peritoneal metastasis from colorectal or appendiceal cancer

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

safety

Key secondary outcomes

1-year overall survival rate


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Maneuver

Interventions/Control_1

Cytoreductive surgery (CRS), Hyperthermic intraperitoneal chemotherapy (HIPEC), Early postoperative intraperitoneal chemotherapy (EPIC)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

Histologically proven colon or appendiceal cancer; peritoneal metastasis; age between 20 and 80 years; Synchronous or metachronous metastasis; Eastern Cooperative Oncology Group performance status 0-1; adequate bone marrow function ; and borderline resectable distant metastasis

Key exclusion criteria

1) Patient who has a history of multiple cancers within 5 years before registration, with the exception of carcinoma in situ and a disease equivalent to intramucosal carcinoma.
2) Patient who is associated with unstable angina pectoris that occurred or worsened within 3 weeks before registration, or patient with a history of cardiac infarction that developed within 6 months before registration.
3) Patient with serious diseases including uncontrolled congestive cardiac failure and abnormal cardiac rhythm.
4) Patient who is associated with or has a history of either fibroid lung or interstitial pneumonia or both. Patient with imaging findings suggestive of the diseases.
5) Patient who is pregnant or breast feeding, or who refuses to use appropriate birth control.
6) Patient whose consent is suspicious in terms of his/her mental and legal state.
7) Patient who is considered by the investigator to be unsuitable for enrollment.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Tomomichi
Middle name
Last name Kiyomatsu

Organization

National Center for Global Health and Medicine

Division name

Department of Surgery

Zip code

162-8655

Address

1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan

TEL

03-3202-7181

Email

tkiyomatsu@hosp.ncgm.go.jp


Public contact

Name of contact person

1st name Yoshimasa
Middle name
Last name Gohda

Organization

National Center for Global Health and Medicine

Division name

Department of Surgery

Zip code

162-8655

Address

1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan

TEL

03-3202-7181

Homepage URL


Email

ygohda@hosp.ncgm.go.jp


Sponsor or person

Institute

National Center for Global Health and Medicine

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Center for Global Helth and Medicine

Address

1-21-1 Toyama, Shinjuku-ku, Tokyo

Tel

0332027181

Email

rinrijm@hosp.ncgm.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 03 Month 03 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 03 Month 01 Day

Date of IRB


Anticipated trial start date

2015 Year 03 Month 01 Day

Last follow-up date

2017 Year 12 Month 31 Day

Date of closure to data entry

2017 Year 12 Month 31 Day

Date trial data considered complete

2017 Year 12 Month 31 Day

Date analysis concluded

2017 Year 12 Month 31 Day


Other

Other related information



Management information

Registered date

2016 Year 03 Month 03 Day

Last modified on

2019 Year 08 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024138


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name